Abstract
Rationale: In a prior study, lumacaftor/ivacaftor treatment (<= 28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not i......
小提示:本篇文献需要登录阅读全文,点击跳转登录